NCT07468916 2026-03-13
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
Jonsson Comprehensive Cancer Center
Phase 2 Not yet recruiting
Clinical Trials
28 trialsNCT02737046 2026-03-10
Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma
University of Miami
Phase 2 Completed
NCT00539591 2025-12-23
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT02001818 2024-08-06
PInNACLe
Australasian Leukaemia and Lymphoma Group
Phase 2 Completed
NCT00846430 2023-08-30
Medical Treatment of "High-Risk" Neurofibromas
Corewell Health West
Phase 2 Completed
NCT00049530 2023-06-29
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00573378 2023-01-25
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT02218164 2022-10-07
Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02982720 2022-02-16
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
Hoosier Cancer Research Network
Phase 2 Terminated
NCT02343224 2022-01-24
Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Emory University
Phase 2 Completed
NCT00525031 2020-09-23
Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00037882 2018-11-01
PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01866553 2018-10-12
Nilotinib Plus Pegylated Interferon-α2b in CML
Amsterdam UMC, location VUmc
Phase 2 Terminated
NCT02155322 2018-08-23
A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00415857 2018-08-21
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00090870 2018-07-12
PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
Medical University of South Carolina
Phase 2 Terminated
NCT00396019 2017-11-06
Study of PEG-Intron for Plexiform Neurofibromas
University of Pittsburgh
Phase 2 Completed
NCT00467077 2017-03-17
Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
California Cancer Consortium
Phase 2 Terminated
NCT00548847 2016-10-26
Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
Emory University
Phase 2 Completed
NCT00045279 2013-06-05
PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00238329 2013-04-08
PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00055809 2013-01-23
Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00276523 2012-10-31
PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00047879 2011-10-26
Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00746746 2011-01-13
A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma
Ochsner Health System
Phase 2 Unknown
NCT00623402 2011-01-12
SoraPeg
University Hospital Schleswig-Holstein
Phase 2 Completed
NCT01227356 2010-10-25
A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia
Uppsala University
Phase 2 Completed
NCT00511121 2007-08-03
Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)
University of Bologna
Phase 2 Terminated